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ABSTRACT
Introduction There are no well- established biomedical 
treatments for the core symptoms of autism spectrum 
disorder (ASD). A small number of studies suggest that 
repetitive transcranial magnetic stimulation (rTMS), a 
non- invasive brain stimulation technique, may improve 
clinical and cognitive outcomes in ASD. We describe 
here the protocol for a funded multicentre randomised 
controlled clinical trial to investigate whether a course of 
rTMS to the right temporoparietal junction (rTPJ), which 
has demonstrated abnormal brain activation in ASD, can 
improve social communication in adolescents and young 
adults with ASD.
Methods and analysis This study will evaluate the 
safety and efficacy of a 4- week course of intermittent 
theta burst stimulation (iTBS, a variant of rTMS) in 
ASD. Participants meeting criteria for Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition ASD 
(n=150, aged 14–40 years) will receive 20 sessions of 
either active iTBS (600 pulses) or sham iTBS (in which 
a sham coil mimics the sensation of iTBS, but no active 
stimulation is delivered) to the rTPJ. Participants will 
undergo a range of clinical, cognitive, epi/genetic, and 
neurophysiological assessments before and at multiple 
time points up to 6 months after iTBS. Safety will be 
assessed via a structured questionnaire and adverse 
event reporting. The study will be conducted from 
November 2020 to October 2024.
Ethics and dissemination The study was approved by 
the Human Research Ethics Committee of Monash Health 
(Melbourne, Australia) under Australia’s National Mutual 
Acceptance scheme. The trial will be conducted according 
to Good Clinical Practice, and findings will be written up for 
scholarly publication.
Trial registration number Australian New Zealand 
Clinical Trials Registry (ACTRN12620000890932).
INTRODUCTION
Autism spectrum disorder (ASD) is a neuro-
developmental disorder that impacts a range 
of domains, including social communication, 
behaviour, cognition, emotion regulation 
and sensorimotor function.1 Core symp-
toms of ASD include social interaction and 
communication problems, and restricted and 
repetitive behaviours. Comorbid neurode-
velopmental disorders (eg, attention deficit 
hyperactivity disorder (ADHD)) and psychi-
atric disorders (eg, depression, anxiety) are 
Strengths and limitations of this study
 ► This multisite randomised controlled trial will be the 
largest trial of repetitive transcranial magnetic stim-
ulation (rTMS) in autism spectrum disorder (ASD) to 
date.
 ► rTMS will be applied to the right temporoparietal 
junction (rTPJ), a cortical region that has demon-
strated abnormal activation in ASD and forms a ma-
jor hub of the ‘social brain’ subnetwork.
 ► Participants will undergo structural MRI scans, with 
rTMS coil position determined via individualised 
neuronavigation.
 ► Adolescent and young adult participants will receive 
rTMS interventions as outpatients, and complete a 
comprehensive range of clinical, neuropsychological 
and neurophysiological assessments.
 ► A limitation of the study is the use of only a sham 
control condition, rather than an additional ‘active 
control’ site to determine whether effects are spe-
cific to rTPJ (rather than a general effect of brain 
stimulation).
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very common,2 3 with the latter often associated with the 
core social communicative difficulties.4 5
Despite the high prevalence of ASD (1 in 59),6 few 
clinical interventions target core symptoms beyond 
early- middle childhood. ASD diagnosis typically occurs 
by the age of 4–6 years,6 and early, intensive interven-
tion throughout these years is associated with the best 
outcomes for individuals with ASD and their families.7 
Unfortunately, there is little clinical support available 
for adolescents and young adults with ASD, who often 
continue to experience social communication symp-
toms that result in barriers to education, employment 
and community participation. As noted, this group also 
experiences extremely poor mental health that is much 
worse than the general population; for instance, lifetime 
depression and anxiety rates are estimated at 37% and 
42%, respectively.2
Non- invasive brain stimulation (NIBS) has emerged 
as a novel, safe and efficacious intervention for a range 
of brain- based disorders. These techniques allow non- 
invasive modulation of specific brain regions via electro-
magnetic or electrical stimulation. The most common 
of these is repetitive transcranial magnetic stimulation 
(rTMS), which is now widely used as an intervention for 
treatment- resistant major depressive disorder.8 It has also 
been established as an intervention for other neurological 
disorders, including migraine and obsessive- compulsive 
disorder.9 10 rTMS is administered via a plastic- coated 
metallic coil that is held against the scalp. This coil emits 
focal, time- varying electromagnetic pulses, which induce 
electrical current in superficial cortical tissue, thus stim-
ulating neurons in the local region. Depending on the 
frequency and strength of pulses administered, rTMS can 
be used to either enhance cortical excitability (ie, upreg-
ulate neural activity), or decrease cortical excitability (ie, 
downregulate neural activity) in the stimulated region. 
This is particularly useful when targeting regions (or 
nodes) of brain networks known to be either underactive 
or overactive in particular conditions. For instance, high- 
frequency (excitatory) rTMS has been used to stimulate 
underactive left dorsolateral prefrontal cortex (DLPFC) 
in treatment- resistant depression,11 while low- frequency 
(inhibitory) rTMS has been used to downregulate exces-
sive activity in left auditory cortex in schizophrenia12 
and supplementary motor area (SMA) in Tourette’s 
disorder.13 Importantly, rTMS also influences broader 
brain networks that involve the stimulated region,14 15 
and this is thought to contribute to its clinical efficacy. 
Here we will stimulate the right temporoparietal junction 
(rTPJ), a key node for social cognition, which is a typical 
area of difficulty among individuals with ASD.16
The brain functions as a set of interconnected 
networks disseminating neuronal information across 
a broad range of distributed areas.17 From a neurobio-
logical perspective, ASD is commonly understood as a 
disorder of synaptic plasticity and neural connectivity, 
leading to abnormalities in brain network connectivity 
between brain regions. These appear to be mediated by 
disruptions in both excitatory (eg, glutamatergic) and 
inhibitory (eg, GABAergic) processes.18 19 There are also 
well- documented abnormalities in local ‘node’ activity, 
particularly within networks that comprise the so- called 
‘social brain,’ including rTPJ.20 21 Indeed, the rTPJ shows 
consistent differences in activation between those with 
and without ASD,16 20–22 while meta- analysis demonstrates 
reduced rTPJ functional connectivity in ASD.23 Accord-
ingly, rTMS to this region has the potential to modulate 
local and regional brain activity within networks impli-
cated in the core social symptoms of ASD.
rTMS is considered a very safe and tolerable tech-
nique. It is typically administered by an experienced clini-
cian (nurse or physician), and patients are monitored 
throughout and at the completion of rTMS administra-
tion. Clinical researchers have established a detailed set of 
safety guidelines, and when rTMS is administered within 
guideline parameters, serious adverse effects are exceed-
ingly rare.24 25 NIBS (including rTMS) is also considered 
very safe for paediatric populations, with a recent study 
showing no adverse effects across 382 children aged 
0–18 years.26
Previously, NIBS has been used to investigate the 
neuropathophysiology of ASD.27–30 More recently, several 
research groups (including ours) have investigated 
whether rTMS could have clinical utility as an interven-
tion in ASD. These studies (see systematic reviews31–33) 
indicate that: low- frequency stimulation of the DLPFC 
can reduce repetitive behaviours, improve neurophys-
iological markers of perception and reduce irritability; 
low- frequency SMA stimulation can improve movement- 
related cortical potentials; and low- frequency stimulation 
of the premotor cortex can improve sensorimotor inte-
gration. While promising, these studies are hampered 
by small sample sizes, a lack of an appropriate control 
condition (placebo or sham stimulation), and moderate- 
to- high risk of bias.31
At present, only two placebo- controlled randomised 
controlled trials (RCTs) have been conducted, both of 
which were double- blind. The first demonstrated that 
2 weeks of daily, high- frequency rTMS to bilateral dorso-
medial prefrontal cortex, compared with sham rTMS, 
improved self- report social- relating symptoms in adults 
with ASD (n=28) 1 month after intervention comple-
tion.34 A recent study demonstrated that 4 weeks of 
high- frequency stimulation of bilateral DLPFC did not 
improve executive function in adolescents and young 
adults with ASD (n=40).35 There was, however, evidence 
for a beneficial effect of rTMS for those with lower adap-
tive functioning at baseline. While providing prelimi-
nary, placebo- controlled support for rTMS in ASD, these 
studies are limited by small sample size.
Rationale/justification
A recent international ‘consensus statement’ provides 
recommendations for future rTMS research in ASD.36 
Considering the clinical heterogeneity of ASD, there 
is agreement that ‘large, multisite, double- blind, 
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placebo- controlled trials with carefully selected neurobi-
ological targets and outcome measures’ are required. It 
is also necessary to understand variability in the response 
to rTMS that can lead to an individualised therapeutic 
approach (ie, personalised medicine approach). These 
include demographic (eg, age, sex), clinical (eg, disorder 
severity, cognitive/symptom profile), neurobiological (eg, 
cortical thickness, structural and functional connectivity), 
and genetic/epigenetic factors. Accordingly, we will 
conduct a large- scale, multisite investigation of the safety 
and efficacy of rTMS in ASD that involves (a) feasible and 
tolerable stimulation paradigms, (b) a carefully selected 
neurobiological target and mode of stimulation, and (c) 
rigorous methodological approaches, including indi-
vidualised stereotactic neuronavigation, an appropriate 
control condition, and efficacious double blinding. If 
successful, this trial will establish a first biomedical inter-
vention to improve social communicative symptoms in 
adolescents and young adults diagnosed with ASD, and 
inform on factors associated with intervention response, 
with anticipated benefits in mental health, quality of life 
and social participation.
Research hypotheses
In ASD, active rTMS to rTPJ, when compared with sham 
rTMS, will be associated with:
1. Improved social communication, measured using the 
Social Responsiveness Scale–Second Edition (SRS-2) 
(evident 1 month after end of rTMS, maintained at 3 
and 6 months) (primary outcome).
2. Improved social cognitive performance, measured us-
ing face processing/face emotion processing neuro-
psychological tasks (evident immediately after rTMS, 
maintained at 1, 3 and 6 months).
3. Improved quality of life, measured using the Personal 
Wellbeing Index (PWI) (evident 1 month after rTMS, 
maintained at 3 and 6 months).
4. Acceptable tolerability and safety (as measured by a 
structured interview and adverse event reporting).
METHODS AND ANALYSIS
Study design and participants
This is a 4- year multicentre Australian study to assess 
the safety and efficacy of a 4- week course of rTMS to 
improve social communication in adolescents and young 
adults diagnosed with ASD. It will be a parallel group 
(between- subjects), double- blind, placebo- controlled 
RCT. Participants will be 150 individuals meeting criteria 
for Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5)1 ASD and aged between 14 and 40 
years. While broad, this age range was selected to ensure 
the feasibility of participant recruitment and to target 
age groups (ie, adolescents and young adults) where 
interventions for ASD are lacking. They will be recruited 
through existing research participant databases, the 
Australian Autism Biobank,37 and advertisements in local 
clinics, advocacy/support groups, and via social media. 
The research team will also engage popular media, both 
locally and nationally, to promote recruitment.
The study will be overseen by a Research Manage-
ment Group, which comprises the 10 chief investigators, 
study coordinator and site coordinators. They will meet 
monthly via video- conference for the duration of the trial. 
There will be 30 participants enrolled at each of the cities 
involved (Brisbane, Sydney, Melbourne, Adelaide, Perth). 
Participants will undergo 20 intervention sessions (one 
per weekday for 4 consecutive weeks) of either active or 
sham (ie, placebo) rTMS. Participants will be assessed 
before and up to 6 months after intervention and in 
accordance with Good Clinical Practice. Assessments will 
evaluate social communication, neuropsychological func-
tion, quality of life, safety and tolerability. There will be 
five primary intervention sites within Australia (Brisbane, 
Sydney, Melbourne, Adelaide, Perth) and additional local 
sites to support recruitment, assessment, genetic analysis, 
and neuroimaging. These will include both university and 
hospital sites. Written informed consent will be obtained 
from participants (or their parent/guardian in the case 
of minors, aged 14–17 years) by a local chief investigator 
or site coordinator. Model participant information and 
consent forms for parents/guardians and adult partici-
pants are provided as online supplemental material 2.
Patient and public involvement
The research team have engaged in extensive consulta-
tion with community groups in recent years, including 
multiple community forums on rTMS. We have also 
consulted with autism organisations when preparing 
advertisements and other study- related communica-
tions. While participants were not directly involved in the 
design of this specific trial, throughout the study we will 
engage a range of community and advocacy groups in 
the implementation of the research, and health service 
partners to ensure rapid translation of our research find-
ings to clinical practice. For instance, the Telethon Kids 
Institute (Western Australia) has established a commu-
nity reference group with whom they regularly consult 
for consumer involvement, and this group will also be 
engaged in the current trial.
rTMS protocol
Participants will receive standard intermittent theta burst 
stimulation (iTBS) to the rTPJ each consecutive weekday 
for a 4- week period (20 sessions). iTBS was chosen as it is 
an ‘excitatory’ paradigm that has the potential to target 
the reduced activation and connectivity commonly seen 
in rTPJ in ASD.16 20 21 23 It can also be administered quickly 
and at a low intensity, which are important considerations 
in this clinical population. Participants will undergo either 
active iTBS or sham iTBS, where a ‘sham coil’ is used to 
mimic the appearance, sound and sensation of rTMS, but 
without delivering electromagnetic stimulation.
Participants will undergo 3T T1 MRI prior to the first 
rTMS session, and stereotactic neuronavigation will 
be used to determine the site of stimulation (Montreal 
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Neurological Institute coordinates x=56, y=−56, z=18; see 
figure 1).
All stimulation will be administered via a Magstim 
Rapid2 stimulator (The Magstim Company, Wales, UK). 
A staff member trained in rTMS will deliver all rTMS 
interventions. A visual resting motor threshold (ie, visual 
observation of muscle activation following TMS pulse) 
will be determined at the right hemisphere/left hand 
prior to the first rTMS session. Each iTBS is delivered 
with the following stimulation parameters:
 ► Burst pattern: three pulses delivered at 50 Hz.
 ► Train duration: bursts repeated five times per second 
(5 Hz) for 2 s (10 bursts).
 ► Intensity: 70% of resting motor threshold.
 ► Intertrain interval: 8 s.
 ► Total time: 200 s (3 min, 20 s).
 ► Total trains: 20.
 ► Total bursts: 200.
 ► Total pulses: 600.
All rTMS procedures, including resting motor 
threshold, will be administered by a TMS clinician who 
is not blinded to study condition. Participants will be 
Figure 1 Site of rTMS coil localisation (MNI coordinates x=56, y=−56, z=18). MNI, Montreal Neurological Institute; rTMS, 
repetitive transcranial magnetic stimulation.
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monitored by study staff for at least 5 min after each inter-
vention session. They can then leave the facility and go 
about their normal daily activities, including driving. The 
participant will be administered the non- invasive brain 
stimulation post- stimulation interview at the end of each 
week of rTMS intervention (ie, after the Friday session) 
to determine the presence/intensity of any side effects. 
For child participants (aged 14–17 years), this interview 
will be conducted with both the parent/guardian and 
the child. Participants will also be regularly asked about 
their well- being during and immediately after each rTMS 
session. Any side effects reported in this manner will be 
documented in the participant’s file and will be exam-
ined at the completion of the trial.
Inclusion and exclusion criteria
Inclusion criteria
 ► Aged 14–40 years.
 ► Meets criteria for ASD based on DSM-5 criteria (clini-
cian reported), and confirmed via Autism Diagnostic 
Observation Schedule–Second Edition (ADOS-2).
 ► English- language fluency/proficiency.
Exclusion criteria
 ► History of seizure/s or epilepsy.
 ► History of severe (traumatic) brain injury.
 ► Contraindication to MRI (eg, claustrophobia, metal 
implants).
 ► Formal verbal IQ assessment <55, as determined by 
Wechsler Abbreviated Scale of Intelligence.
 ► Comorbid neurological or psychiatric diagnosis not 
commonly associated with ASD (eg, psychosis).
 ► Unstable medical condition.
 ► Unstable medication regimen, or medication 
contraindicated for TMS.
 ► Pregnancy or current breast feeding.
 ► Substance use/abuse disorder.
 ► Concurrent intervention targeting social 
communication.
 ► Evidence of significant epileptiform activity on elec-
troencephalogram (EEG) (eg, seizures on EEG, runs 
of epileptiform discharges).
Outcome measures
Data collection and study timings are presented in table 1. 
Participants are assessed prior to rTMS (T0), and at four 
points after rTMS: T1 (immediately after rTMS), T2 
(1 month after completion of rTMS), T3 (3 months after 
completion of rTMS) and T4 (6 months after completion 
of rTMS).
The primary outcome measure is the SRS-2 (school- age 
autoscore form for parent/guardian (parent/guardian 
report)/adult autoscore form for informant (infor-
mant report)) total T- score, while the primary outcome 
point will be at 1 month after completion of rTMS (T2) 
compared with pre- rTMS (T0). For adult participants, 
an informant (parent/relative/friend) will complete the 
SRS-2 with respect to the participant.
Secondary outcomes encompass a range of clinical, 
neuropsychological, neurophysiological and biolog-
ical measures. Clinical measures include: Conners 3 
(parent/guardian report)/Conners Adult ADHD Rating 
Scales (informant report and adult self- report); Aber-
rant Behaviour Checklist–Second Edition (parent/
guardian/informant report); Behaviour Rating Scale of 
Executive Function, Second Edition (BRIEF)/BRIEF–
Adult Version (parent/guardian/informant report and 
adult self- report); WHO Disability Assessment Schedule 
2.0 (parent/guardian/informant report); Depres-
sion, Anxiety and Stress Scale (self- report); and PWI 
(self- report).
Neuropsychological measures include: Reading the 
Mind in the Eyes Test; Benton Facial Recognition Test; 
Cambridge Face Memory Test; National Institutes of 
Health Cognition Toolbox; and Working Memory 
Assessment.
Neurophysiological measures include: resting- state 
EEG and face processing event- related potentials.
The neuropsychological and neurophysiological 
measures were selected as they are associated with acti-
vation of the target cortical region (eg,38); while there 
were additional paradigms that could have been used (eg, 
biological motion processing), we were mindful of not 
overburdening our participants and selected those that 
we felt most relevant to our social communication target.
Finally, a buccal swab will be administered both before 
and after the course of rTMS, which will allow an inves-
tigation of genetic and epigenetic predictors of interven-
tion response, and potential epigenetic changes following 
rTMS.
The various electrophysiological and genetic measures 
that are being collected are highly exploratory but may 
help us to understand mechanisms by which rTMS exerts 
an influence on social communication.
Randomisation
There will be an equal number of participants allocated to 
each condition at each of the five project sites (15 active, 
15 sham; total 75 active, 75 sham). A computerised adap-
tive randomisation procedure (minimisation method) 
will be performed, adjusting for baseline characteris-
tics (age, sex, SRS T0 score),39 which ensures a balance 
of conditions across trial sites. Randomisation will be 
completed by the chief investigator, who will provide this 
information to the intervention clinicians (who are not 
blinded) via email.
Statistical analysis and data management
With respect to statistical power, allowing for 10% attrition 
of our 150 participants, and based on the estimated effect 
size from our previously published RCT (which revealed 
a moderate effect of rTMS),34 a sample size of n=135 in 
a mixed- model (two groups, five time points) will yield 
power of 0.99 (f=0.20, α=0.01). While this sample size is 
larger than the minimum suggested by a priori power 
analysis (n=64, based on f=0.20, α=0.01, power=0.95), 
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this will enable exploratory analysis to determine demo-
graphic, clinical, neuroimaging and genetic predictors of 
treatment response.
On enrolment, participants will be allocated a unique 
study identification code. Their name will not appear 
with the research data collected. All data will be stored in 
REDCap40 and on secure network locations governed by 
Deakin University. All chief investigators will have access 
to the final trial dataset. Any information obtained in 
connection with this research project that can identify a 
participant will remain confidential. Where a participant 
elects to withdraw from the study, we will retain and use 
any data collected prior to withdrawal.
Random effects linear mixed models will be used to 
ensure the inclusion of participants who have missing 
data, including those that withdraw from the study. Specif-
ically, this will involve a between- subjects factor (rTMS 
condition: active vs placebo) and a within- subjects factor 
(time of assessment: pre vs post vs 1 month vs 3 months vs 
6 months), with participant and site entered as random 
effects. We will employ an intention- to- treat frame-
work for these analyses. We will examine rTMS safety by 
exploring descriptive statistics arising from the structured 
questionnaire related to the development of possible 
side effects. An interim analysis will be performed at the 
midpoint of data collection for possible trial futility. The 
above- mentioned a priori power analysis, where n=64 is 
required to detect a moderate effect, suggests that we will 
be sufficiently powered to detect an effect of rTMS in this 
interim analysis.
Table 1 Data collection and study timings
Visits Pre- enrolment T0 Tx T1 T2 T3 T4
Screening X X
Written informed consent X
Randomisation X
Demographics X X
Medical history X X
Neuroimaging (MRI) X
Clinical EEG X
Buccal swab X X
ADOS-2 X
WASI-2 X
rTMS intervention (active/sham) X
NIBS:PSI X
SRS-2 X X X X X
Conners-3/CAARS X X X X X
ABC-2 X X X X X
BRIEF/BRIEF- A X X X X X
DASS X X X X X
PWI X X X X X
WHODAS 2.0 X X X X X
NIH Cognition Toolbox X X X X
RMET X X X X
BFRT X X X X
CFMT X X X X
Working Memory X X X X
rsEEG X X
FP- ERP X X
ABC-2, Aberrant Behaviour Checklist, Second Edition; ADHD, attention deficit hyperactivity disorder; ADOS-2, Autism Diagnostic Observation 
Schedule, Second Edition; BFRT, Benton Facial Recognition Test; BRIEF, Brief Rating Inventory of Executive Function; BRIEF- A, BRIEF–Adult 
Version; CAARS, Conners Adult ADHD Rating Scales; CFMT, Cambridge Face Memory Test; DASS, Depression, Anxiety and Stress Scale; 
EEG, electroencephalography; FP- ERP, face- processing event- related potentials; NIBS:PSI, non- invasive brain stimulation post- stimulation 
interview; NIH, National Institutes of Health; PWI, Personal Wellbeing Index; RMET, Reading the Mind in the Eyes Test; rsEEG, resting- state 
EEG; rTMS, repetitive transcranial magnetic stimulation; SRS-2, Social Responsiveness Scale, Second Edition; T0, pre- rTMS; T1, week 
following rTMS; T2, 1 month after completion of rTMS; T3, 3 months after completion of rTMS; T4, 6 months after completion of rTMS; WASI-
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Exploratory analyses will be undertaken to investigate 
factors, including genetic variants and structural/func-
tional neuroimaging (eg, diffusion MRI, resting- state 
functional MRI), that influence intervention response, 
and to investigate epigenetic changes following rTMS. 
We will use linear mixed models to determine the effect 
of rTMS on SRS-2 score, but with additional independent 
variables (eg, age, sex, cognitive ability, ADOS-2 symptom 
severity, rTPJ structural and functional connectivity 
within the social brain subnetwork, polygenic risk score 
for ASD41).
Epigenetic variation refers to variation in chromatin 
structure, which is associated with variation in gene 
expression. In contrast to DNA, epigenetic variation can 
change over time, for example, following treatment.42 
Accordingly, we will compare epigenetic variation for 
DNA samples collected before and after rTMS and inves-
tigate any associations with intervention response (see 
online supplemental material 1 for a statement on biolog-
ical specimens).
At the conclusion of the project, all electronic and 
hard copy data will be archived within Deakin Univer-
sity (Information and Records Services). Electronic data 
will be retained on secure Deakin University servers and 
archived in REDCap, but also transferred to physical hard 
drives for archival storage. As some hard copy data will be 
stored at each site (eg, signed consent forms, clinical files 
used during rTMS intervention), these will be securely 
couriered to Deakin University for archiving. Each site will 
be required to delete any electronic data that may remain 
at their site. As this is a clinical trial involving child partic-
ipants, data will be retained indefinitely. Any published 
work from this study will be accompanied by publicly 
available deidentified data through the Open Science 
Framework ( osf. io). The research team, including both 
chief investigators and associate investigators, all have the 
opportunity to conduct secondary analyses. This will be 
negotiated with the trial’s Research Management Group, 
which comprises the 10 chief investigators. Data may also 
be shared with external (national and international) 
collaborators to obtain larger sample sizes, which are 
often necessary to achieve the statistical power necessary 
to analyse biomarker data. This could include specific 
research projects or online data repositories, which may 
be accessed and used by external researchers.
Blinding
This is a double- blind study; accordingly, participants 
(and their parents/guardians, where relevant) and the 
testing researchers/statisticians will be blinded to inter-
vention condition. The individual administering rTMS 
must select the appropriate coil (ie, active or sham) and 
will therefore not be blinded, but this individual will not 
conduct any of the assessment or be involved in the statis-
tical analyses. Unblinding may occur in the event of an 
adverse event. We will assess blinding integrity by asking 
participants to indicate, at the end of their 4- week inter-
vention, which condition they believed they received and 
the confidence (on an 11- point scale) in this judgement. 
At the conclusion of the final assessment (T4), participants 
will be unblinded as to their intervention condition by a 
member of the research team who is not blinded. Those 
who were allocated to the sham rTMS intervention will be 
offered the opportunity to undergo the real rTMS inter-
vention. While this will occur after all assessments have 
been administered, scored and entered into REDCap, we 
have developed standard operating procedures to mini-
mise the likelihood that assessors will encounter partici-
pants completing the open- label component.
Safety
Participants will undergo extensive screening to ensure 
that they meet safety criteria for undergoing rTMS.25 
For child participants, a parent or legal guardian will 
complete the screening. Participants will undergo EEG 
prior to their first rTMS session, and this will be reviewed 
by the trial neurologist. Any participants demonstrating 
evidence of runs of epileptiform discharges, as assessed by 
the study neurologist, will be withdrawn from the study. 
At the beginning of their first session, participants (or 
their parent/guardian for child participants) will again 
be screened to ensure that they can undergo rTMS.
A Data Safety Monitoring Board (DSMB) will be 
formed. This DSMB will comprise three senior clinical 
researchers independent to the current project. The 
DSMB will meet twice per year to review the conduct of 
the trial and monitor study data. They will also review any 
serious adverse events in a mid- trial safety analysis and 
on an ad hoc basis. Terms of reference will be based on 
advice from the National Health and Medical Research 
Council’s DSMB documentation.
Adverse events will be reported to the relevant Human 
Research Ethics Committees (HRECs) immediately, and 
no later than 72 hours after the event. Depending on the 
nature and severity of the event, it may be necessary to 
also report to other regulatory bodies (eg, Therapeutic 
Goods Administration) and suspend or terminate the 
trial. Should an individual suffer harm from trial partic-
ipation, they will receive medical treatment required 
to treat the injury or complication, free of charge, as a 
public patient in any Australian public hospital.
Ethics and dissemination
This study has been approved by the Monash Health 
HREC (Melbourne, Australia; RES-20-0000- 606A) under 
the National Mutual Acceptance scheme, which allows for 
mutual scientific and ethical acceptance across Australian 
jurisdictions and institutions. We will engage a range of 
community and advocacy groups in the implementation 
of the study, and health service partners to ensure rapid 
translation of our research findings to clinical practice.
The health outcomes of this study will be provided 
within 12 months of the trial’s completion, initially 
through a freely accessible preprint and an open- access 
peer- reviewed journal publication. Authorship will be 
determined according to the standards outlined in the 
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National Health and Medical Research Council’s Austra-
lian Code for the Responsible Conduct of Research. Chief 
investigators will also present the study findings at rele-
vant scientific conferences and autism advocacy/support 
group community forums. The research team will also 
engage in more extensive public outreach and dissemi-
nate study findings widely through appropriate channels 
(eg, study website, social media, news outlets). These 
dissemination pathways will also involve contributing to 
clinical guidelines (and direct engagement with health-
care providers).
Participants will be sent a plain language summary 
detailing the study results at the completion of the trial. 
This summary will be written as a lay summary and in a 
manner accessible to participants and their families. A 
child version will also be sent to parents/guardians to 
share with their child. The summary will contain no iden-
tifying information and provide only group- level results.
This project involves the collection of a large number 
of measures (eg, clinical, neuropsychological, neuroim-
aging, genetic/epigenetic) and it is expected that the 
chief investigators will conduct further exploratory anal-
yses on these data. This might include, for example, exam-
ining neuroimaging and genetic predictors of response to 
rTMS intervention and characterising epigenetic changes 
following rTMS.
Trial status
At the time of submission, recruitment has not 
commenced.
Author affiliations
1School of Psychology, Deakin University, Geelong, Victoria, Australia
2Central Clinical School, Monash University, Melbourne, Victoria, Australia
3Child Health Research Centre, The University of Queensland, South Brisbane, 
Queensland, Australia
4Children's Health Queensland Hospital and Health Service, South Brisbane, 
Queensland, Australia
5Autism Clinic for Translational Research, Brain and Mind Centre, Children’s Hospital 
Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, 
Camperdown, New South Wales, Australia
6Telethon Kids Institute, Perth, Western Australia, Australia
7University of Western Australia, Crawley, Western Australia, Australia
8Discipline of Psychiatry, The University of Adelaide, Adelaide, South Australia, 
Australia
9Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health 
and Medical Research Institute, Adelaide, South Australia, Australia
10Turner Institute for Brain and Mental Health, School of Psychological Sciences 
and Monash Biomedical Imaging, Monash University, Melbourne, Victoria, 
Australia
11Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, 
Murdoch, Western Australia, Australia
12Discipline of Psychology, Murdoch University, Murdoch, Western Australia, 
Australia
13Brain and Mind Centre, Central Clinical School, Faculty of Medicine and Health, 
The University of Sydney, Camperdown, New South Wales, Australia
14IMPACT – the Institute for Mental and Physical Health and Clinical Translation, 
School of Medicine, Deakin University, Geelong, Victoria, Australia
15Krongold Clinic, Monash Education, Monash University, Clayton, Victoria, Australia
16Centre for Human Psychopharmacology, Faculty of Heath, Arts and Design, 
Swinburne University of Technology, Melbourne, Victoria, Australia
17Epworth Centre for Innovation in Mental Health, Epworth HealthCare, Camperwell, 
Victoria, Australia
Contributors PGE, KB, AJG, ML, NR, CM, SC, A- MV, KB, IBH, CG, HF, HH, JC, MK, 
NM, PD and PF contributed to the design of the study. PGE, KB, ML, NR, CM, SC, 
A- MV, KB, AJOW, GA, MK, PD, TF, KC, NA- U, SB and PF contributed to the writing of 
the manuscript. All authors approved the final draft of the manuscript.
Funding This project has been funded by the National Health and Medical 
Research Council (NHMRC) under the Medical Research Future Fund (MRFF) 
Neurological Disorders 2020 scheme (Application ID: APP1199298).
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Peter G Enticott http:// orcid. org/ 0000- 0002- 6638- 951X
Karen Barlow http:// orcid. org/ 0000- 0003- 2612- 8507
Adam J Guastella http:// orcid. org/ 0000- 0001- 8178- 4625
Melissa K Licari http:// orcid. org/ 0000- 0003- 3705- 5323
Nigel C Rogasch http:// orcid. org/ 0000- 0002- 4484- 1069
Christel M Middeldorp http:// orcid. org/ 0000- 0002- 6218- 0428
Ann- Maree Vallence http:// orcid. org/ 0000- 0001- 9190- 6366
Kelsie A Boulton http:// orcid. org/ 0000- 0002- 9408- 7367
Ian B Hickie http:// orcid. org/ 0000- 0001- 8832- 9895
Cherrie Galletly http:// orcid. org/ 0000- 0001- 6185- 9677
Gail A Alvares http:// orcid. org/ 0000- 0003- 3351- 5919
Hakuei Fujiyama http:// orcid. org/ 0000- 0002- 7546- 6636
Helen Heussler http:// orcid. org/ 0000- 0003- 0666- 7810
Jeffrey M Craig http:// orcid. org/ 0000- 0003- 3979- 7849
Melissa Kirkovski http:// orcid. org/ 0000- 0003- 3395- 8525
Natalie T Mills http:// orcid. org/ 0000- 0003- 3255- 5118
Nicole J Rinehart http:// orcid. org/ 0000- 0001- 6109- 3958
Peter H Donaldson http:// orcid. org/ 0000- 0001- 7715- 8891
Talitha C Ford http:// orcid. org/ 0000- 0001- 5400- 2659
Karen Caeyenberghs http:// orcid. org/ 0000- 0001- 7009- 6843
Natalia Albein- Urios http:// orcid. org/ 0000- 0001- 7841- 018X
Soukayna Bekkali http:// orcid. org/ 0000- 0002- 8055- 0365
Paul B Fitzgerald http:// orcid. org/ 0000- 0003- 4217- 8096
REFERENCES
 1 American Psychiatric Association. Diagnostic and statistical manual 
of mental disorders. 5th ed. Arlington, VA: American Psychiatric 
Association, 2013.
 2 Hollocks MJ, Lerh JW, Magiati I, et al. Anxiety and depression in 
adults with autism spectrum disorder: a systematic review and meta- 
analysis. Psychol Med 2019;49:559–72.
 3 Rau S, Skapek MF, Tiplady K, et al. Identifying comorbid ADHD in 
autism: attending to the inattentive presentation. Res Autism Spectr 
Disord 2020;69:101468.
 4 Day TC, McNaughton KA, Naples AJ, et al. Self- Reported social 
impairments predict depressive disorder in adults with autism 
spectrum disorder. Autism 2020;24:297-306.
 5 van Steensel FJA, Bögels SM, Perrin S. Anxiety disorders in children 
and adolescents with autistic spectrum disorders: a meta- analysis. 
Clin Child Fam Psychol Rev 2011;14:302–17.
 6 Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism 
spectrum disorder among children aged 8 years — autism and 









pen: first published as 10.1136/bm




9Enticott PG, et al. BMJ Open 2021;11:e046830. doi:10.1136/bmjopen-2020-046830
Open access
developmental disabilities monitoring network, 11 sites, United 
States, 2014. MMWR Surveill. Summ. 2018;67:1–23.
 7 Landa RJ. Efficacy of early interventions for infants and young 
children with, and at risk for, autism spectrum disorders. Int Rev 
Psychiatry 2018;30:25–39.
 8 George MS, Lisanby SH, Avery D, et al. Daily left prefrontal 
transcranial magnetic stimulation therapy for major depressive 
disorder: a sham- controlled randomized trial. Arch Gen Psychiatry 
2010;67:507–16.
 9 Feng Y, Zhang B, Zhang J, et al. Effects of non- invasive brain 
stimulation on headache intensity and frequency of headache 
attacks in patients with migraine: a systematic review and meta- 
analysis. Headache 2019;59:1436–47.
 10 Rapinesi C, Kotzalidis GD, Ferracuti S, et al. Brain stimulation in 
obsessive- compulsive disorder (OCD): a systematic review. Curr 
Neuropharmacol 2019;17:787–807.
 11 Luber BM, Davis S, Bernhardt E, et al. Using neuroimaging to 
individualize TMS treatment for depression: toward a new paradigm 
for imaging- guided intervention. Neuroimage 2017;148:1–7.
 12 Blumberger DM, Fitzgerald PB, Mulsant BH, et al. Repetitive 
transcranial magnetic stimulation for refractory symptoms in 
schizophrenia. Curr Opin Psychiatry 2010;23:85–90.
 13 Hsu C- W, Wang L- J, Lin P- Y. Efficacy of repetitive transcranial 
magnetic stimulation for Tourette syndrome: a systematic review and 
meta- analysis. Brain Stimul 2018;11:1110–8.
 14 Tik M, Hoffmann A, Sladky R, et al. Towards understanding 
rTMS mechanism of action: stimulation of the DLPFC causes 
network- specific increase in functional connectivity. Neuroimage 
2017;162:289–96.
 15 Caeyenberghs K, Duprat R, Leemans A, et al. Accelerated 
intermittent theta burst stimulation in major depression induces 
decreases in modularity: a connectome analysis. Netw Neurosci 
2019;3:157–72.
 16 Lombardo MV, Chakrabarti B, Bullmore ET, et al. Specialization of 
right temporo- parietal junction for mentalizing and its relation to 
social impairments in autism. Neuroimage 2011;56:1832–8.
 17 Bullmore E, Sporns O. The economy of brain network organization. 
Nat Rev Neurosci 2012;13:336–49.
 18 Coghlan S, Horder J, Inkster B, et al. Gaba system dysfunction in 
autism and related disorders: from synapse to symptoms. Neurosci 
Biobehav Rev 2012;36:2044–55.
 19 Hull JV, Dokovna LB, Jacokes ZJ, et al. Resting- State functional 
connectivity in autism spectrum disorders: a review. Front Psychiatry 
2016;7:205.
 20 Patriquin MA, DeRamus T, Libero LE, et al. Neuroanatomical and 
neurofunctional markers of social cognition in autism spectrum 
disorder. Hum Brain Mapp 2016;37:3957–78.
 21 Philip RCM, Dauvermann MR, Whalley HC, et al. A systematic review 
and meta- analysis of the fMRI investigation of autism spectrum 
disorders. Neurosci Biobehav Rev 2012;36:901–42.
 22 Kirkovski M, Enticott PG, Hughes ME, et al. Atypical neural activity in 
males but not females with autism spectrum disorder. J Autism Dev 
Disord 2016;46:954–63.
 23 Wang W, Liu J, Shi S, et al. Altered resting- state functional activity in 
patients with autism spectrum disorder: a quantitative meta- analysis. 
Front Neurol 2018;9:556.
 24 Lerner AJ, Wassermann EM, Tamir DI. Seizures from transcranial 
magnetic stimulation 2012-2016: results of a survey of active 
laboratories and clinics. Clin Neurophysiol 2019;130:1409–16.
 25 Rossi S, Hallett M, Rossini PM, et al. Safety, ethical considerations, 
and application guidelines for the use of transcranial magnetic 
stimulation in clinical practice and research. Clin Neurophysiol 
2009;120:2008–39.
 26 Zewdie E, Ciechanski P, Kuo HC, et al. Safety and tolerability of 
transcranial magnetic and direct current stimulation in children: 
prospective single center evidence from 3.5 million stimulations. 
Brain Stimul 2020;13:565-575.
 27 Cole EJ, Barraclough NE, Enticott PG. Investigating mirror system 
(MS) activity in adults with ASD when inferring others' intentions 
using both TMS and EEG. J Autism Dev Disord 2018;48:2350–67.
 28 Enticott PG, Kennedy HA, Rinehart NJ, et al. Gabaergic activity in 
autism spectrum disorders: an investigation of cortical inhibition 
via transcranial magnetic stimulation. Neuropharmacology 
2013;68:202–9.
 29 Enticott PG, Kennedy HA, Rinehart NJ, et al. Mirror neuron activity 
associated with social impairments but not age in autism spectrum 
disorder. Biol Psychiatry 2012;71:427–33.
 30 Kirkovski M, Rogasch NC, Saeki T, et al. Single pulse transcranial 
magnetic Stimulation- Electroencephalogram reveals no 
electrophysiological abnormality in adults with high- functioning 
autism spectrum disorder. J Child Adolesc Psychopharmacol 
2016;26:606–16.
 31 Barahona- Corrêa JB, Velosa A, Chainho A, et al. Repetitive 
transcranial magnetic stimulation for treatment of autism spectrum 
disorder: a systematic review and meta- analysis. Front Integr 
Neurosci 2018;12:27.
 32 Enticott PG, Kirkovski M, Oberman LM. Transcranial magnetic 
stimulation in autism spectrum disorder. In: Oberman LM, Enticott 
PG, eds. Neurotechnology and brain stimulation in pediatric 
psychiatric and neurodevelopmental disorders. London, UK: Elsevier, 
2019.
 33 Oberman LM, Enticott PG, Casanova MF, et al. Transcranial magnetic 
stimulation in autism spectrum disorder: challenges, promise, and 
roadmap for future research. Autism Res 2016;9:184–203.
 34 Enticott PG, Fitzgibbon BM, Kennedy HA, et al. A double- blind, 
randomized trial of deep repetitive transcranial magnetic stimulation 
(rTMS) for autism spectrum disorder. Brain Stimul 2014;7:206–11.
 35 Ameis SH, Blumberger DM, Croarkin PE, et al. Treatment of 
executive function deficits in autism spectrum disorder with repetitive 
transcranial magnetic stimulation: a double- blind, sham- controlled, 
pilot trial. Brain Stimul 2020;13:539–47.
 36 Cole EJ, Enticott PG, Oberman LM, et al. The potential of repetitive 
transcranial magnetic stimulation for autism spectrum disorder: a 
consensus statement. Biol Psychiatry 2019;85:e21–2.
 37 Alvares GA, Dawson PA, Dissanayake C, et al. Study protocol for 
the Australian autism Biobank: an international resource to advance 
autism discovery research. BMC Pediatr 2018;18:284.
 38 Gao C, Conte S, Richards JE, et al. The neural sources of N170: 
understanding timing of activation in face- selective areas. 
Psychophysiology 2019;56:e13336–e36.
 39 Kenjo Y, Antoku Y, Akazawa K, et al. An easily customized, random 
allocation system using the minimization method for multi- 
institutional clinical trials. Comput Methods Programs Biomed 
2000;62:45–9.
 40 Harris PA, Taylor R, Minor BL, et al. The REDCap Consortium: 
building an international community of software platform partners. J 
Biomed Inform 2019;95:103208.
 41 Grove J, Ripke S, Als TD, et al. Identification of common genetic risk 
variants for autism spectrum disorder. Nat Genet 2019;51:431–44.
 42 Kular L, Kular S. Epigenetics applied to psychiatry: clinical 
opportunities and future challenges. Psychiatry Clin Neurosci 
2018;72:195–211.









pen: first published as 10.1136/bm
jopen-2020-046830 on 7 July 2021. D
ow
nloaded from
 
